| Pablo J Labadie, MD | |
|
1111 Medical Center Blvd, S-650, Marrero, LA 70072 | |
| (504) 934-8100 | |
| (504) 934-8102 |
| Full Name | Pablo J Labadie |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 33 Years |
| Location | 1111 Medical Center Blvd, Marrero, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427078898 | NPI | - | NPPES |
| 1480355 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 09416R (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Jefferson Medical Center | Marrero, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New Orleans Physician Services Inc | 5294057824 | 124 |
News Archive
MediciNova today announced the enrollment of patients in a Phase II clinical study with MN-166 for the treatment of multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. MN-166 is an orally administered drug with a novel mechanism of action that includes the inhibition of phosphodiesterase IV.
Preterm birth occurs before 37 weeks of gestation and has been tied to many complications in the infant. In Canada, the rate of survival of very preterm infants born between 28 to 32 weeks, improved by 25 percent, thanks to the national Evidence-based Practice for Improving Quality (EPIQ) program in neonatal intensive care units (NICUs) across the country.
Almost from the moment COVID-19 reached this nation's shores, nursing homes have experienced some of its most devastating effects.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
› Verified 1 days ago
| Entity Name | New Orleans Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396169678 PECOS PAC ID: 5294057824 Enrollment ID: O20141209002021 |
News Archive
MediciNova today announced the enrollment of patients in a Phase II clinical study with MN-166 for the treatment of multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. MN-166 is an orally administered drug with a novel mechanism of action that includes the inhibition of phosphodiesterase IV.
Preterm birth occurs before 37 weeks of gestation and has been tied to many complications in the infant. In Canada, the rate of survival of very preterm infants born between 28 to 32 weeks, improved by 25 percent, thanks to the national Evidence-based Practice for Improving Quality (EPIQ) program in neonatal intensive care units (NICUs) across the country.
Almost from the moment COVID-19 reached this nation's shores, nursing homes have experienced some of its most devastating effects.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pablo J Labadie, MD 1111 Medical Center Blvd, S-650, Marrero, LA 70072 Ph: (504) 934-8100 | Pablo J Labadie, MD 1111 Medical Center Blvd, S-650, Marrero, LA 70072 Ph: (504) 934-8100 |
News Archive
MediciNova today announced the enrollment of patients in a Phase II clinical study with MN-166 for the treatment of multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. MN-166 is an orally administered drug with a novel mechanism of action that includes the inhibition of phosphodiesterase IV.
Preterm birth occurs before 37 weeks of gestation and has been tied to many complications in the infant. In Canada, the rate of survival of very preterm infants born between 28 to 32 weeks, improved by 25 percent, thanks to the national Evidence-based Practice for Improving Quality (EPIQ) program in neonatal intensive care units (NICUs) across the country.
Almost from the moment COVID-19 reached this nation's shores, nursing homes have experienced some of its most devastating effects.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
› Verified 1 days ago
Dr. Jon Ryan Glass, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1111 Medical Center Blvd, S-650, Marrero, LA 70072 Phone: 504-934-8100 Fax: 504-934-8102 | |
Matthew Donald Strain, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1111 Medical Center Blvd Ste 650, Marrero, LA 70072 Phone: 504-934-8100 | |
Jules S Deutsch, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1111 Medical Center Blvd, Suite 313n, Marrero, LA 70072 Phone: 504-371-0071 Fax: 504-371-0272 | |
W. Aaron Caraway, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1111 Medical Center Blvd, Suite 313n, Marrero, LA 70072 Phone: 504-371-0071 Fax: 504-689-2613 | |
Gregory Paul Larsen, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1111 Medical Center Blvd, Suite 313, Marrero, LA 70072 Phone: 504-842-4083 | |
Glenn R Landry, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1111 Medical Center Blvd, Suite 313n, Marrero, LA 70072 Phone: 504-371-0071 Fax: 507-371-0272 |